Infection prevention, employment retention, cost control and flexible production control during the COVID-19 pandemic
First written in FY2021-Q3. 9 of 11 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2024: 1 of 10 companies on the "Worse" side.
5 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual reportThe individual disclosure explaining the infection prevention, employment retention, cost control and flexible production control presented in the previous filing as an integrated response to COVID-19 is not separately presented in this securities report.
- FY2023RestatedAnnual report
「Amid the prolonged COVID-19 pandemic, we continued to thoroughly implement infection-prevention measures for customers and employees, while working to improve productivity, optimise staffing, reduce costs and maintain appropriate inventory levels.」
The response to COVID-19 through infection prevention, productivity improvement, staffing optimization, cost reduction and maintenance of appropriate inventory levels has continued throughout the full year. - FY2023-Q3RestatedAnnual report
「In terms of earnings, in addition to the effect of higher revenue, increased productivity resulting from an efficient production structure and optimization of store staffing structures,」
Efficient production systems, higher productivity and optimization of store staffing have continued as operating and cost measures since the spread of COVID-19. - FY2023-Q2RestatedAnnual report
「In terms of earnings, in addition to the effect of higher revenue, increased productivity resulting from an efficient production structure and optimization of store staffing structures,」
Efficient production systems, higher productivity and optimization of store staffing have continued as cost and operating measures during the COVID-19 pandemic. - FY2023-Q1RestatedAnnual report
「Amid the prolonged COVID-19 pandemic, we continued to thoroughly implement infection-prevention measures for customers and employees while working to improve productivity and optimize staffing allocations in line with changes in revenue.」
The response to COVID-19 through infection prevention, productivity improvement and optimization of staffing in line with sales fluctuations has continued. - FY2022RestatedAnnual report
「Amid the prolonged COVID-19 pandemic, we continued to thoroughly implement infection-prevention measures for customers and employees, while working to improve productivity, optimise staffing, reduce costs and maintain appropriate inventory levels.」
The response to COVID-19 through infection prevention, productivity improvement, staffing optimization, cost reduction and maintenance of appropriate inventory levels has continued. - FY2022-Q3RestatedAnnual report
「Amid the prolonged COVID-19 pandemic, we continued to thoroughly implement infection-prevention measures for customers and employees, while working to improve productivity, optimise staffing, reduce costs and maintain appropriate inventory levels.」
While continuing infection prevention measures, we are working to improve productivity, optimize staffing, reduce costs and maintain appropriate inventory levels. - FY2022-Q2RestatedAnnual report
「Amid the prolonged COVID-19 pandemic, we continued to thoroughly implement infection-prevention measures for customers and employees, while working to improve productivity, optimise staffing, reduce costs and maintain appropriate inventory levels.」
While continuing infection prevention measures, we are working to improve productivity, optimize staffing, reduce costs and maintain appropriate inventory levels. - FY2022-Q1RestatedAnnual report
「Amid the prolonged COVID-19 pandemic, we continued to thoroughly implement infection-prevention measures for customers and employees, reduce capital investment and other expenses, review staffing allocations in line with changes in revenue, and appropriately control product volumes.」
The response to COVID-19 through infection prevention, reductions in capital investment and expenses, a review of staffing and control of product volumes has been reconfirmed. - FY2021RestatedAnnual report
「As part of our response to COVID-19, we thoroughly implemented infection prevention measures for customers and employees, worked to maintain employment while ensuring appropriate staffing, and pursued reductions in capital investment and expenses, as well as appropriate control of product volumes in response to fluctuations in sales.」
The full-year response to COVID-19 combining infection prevention, employment retention, staffing, reductions in capital investment and expenses, and control of product volumes has been reconfirmed. - FY2021-Q3First statedAnnual report
「In response to the COVID-19 pandemic, we thoroughly implemented infection-prevention measures, sought to control labour costs while maintaining employee employment and reduce expenses, and worked to flexibly control production in response to fluctuations in sales.」
As measures to address COVID-19, infection prevention, employment retention, control of personnel expenses, reduction of operating expenses and production control aligned with sales fluctuations are disclosed together for the first time.